phase II clinical study FDA Approves Takeda's Exkivity With Thermo Fisher CDx for EGFR Exon20 Insertion-Positive NSCLC This is the first time the FDA has approved a drug specifically for NSCLC patients who harbor rare EGFR Exon20 insertion mutations. Burning Rock Biotech, Impact Therapeutics Partner on CDx for PARP Inhibitor Senaparib The NGS firm will work with Impact to develop companion diagnostics to select patients eligible for Impact's synthetic lethality drugs, beginning with senaparib. Genomic Testing Cooperative to ID Patients for Elevation Oncology's Seribantumab Trial GTC will use its Solid Tumor Profile Plus test to identify solid cancer patients with NRG1 gene fusions for enrollment in Elevation's Phase II CRESTONE trial. Rain Therapeutics, Tempus Partner to Identify Patients with MDM2-Amplified Tumors for Basket Trial Tempus will provide centralized DNA and RNA tumor sequencing to help Rain enroll patients in a Phase II trial for its MDM2 inhibitor. NeoGenomics, Elevation Oncology Partner on NRG1 Fusion Testing for Clinical Trial Enrollment NeoGenomics will use its gene fusion panels to identify patients with solid tumors and an NRG1 fusion who might qualify for Elevation's Phase II CRESTONE study. Feb 25, 2021 Kronos Bio Doses First Patient in CDK9 Inhibitor Trial With Tempus Performing Sequencing Jan 28, 2021 OmniSeq, UPMC Partner on Immunotherapy Trial Matching for Head and Neck Cancer Dec 17, 2020 Merus, Sema4 Partner to Accelerate Enrollment in Zenocutuzumab Trial Nov 23, 2020 Novellus, Tempus Partner to Enroll Patients in BRAF Inhibitor Clinical Trial Program Nov 23, 2020 Genentech, OneOncology Partner on Genomic Profiling for Personalized Cancer Care Oct 16, 2020 NGS-Based Profiling May Guide Treatment for Patients With Cancers of Unknown Primary Oct 2, 2020 Natera Molecular Residual Disease Test to be Used in Breast Cancer Trial of Ibrance Aug 27, 2020 Natera, MGH to Collaborate in Early-Stage Breast Cancer Clinical Trial of Targeted Therapy Aug 13, 2020 Strata, Mirati Therapeutics Partner on Tumor-Agnostic Clinical Trial of Novel KRAS G12C Inhibitor Aug 11, 2020 Caris Life Sciences, Elevation Oncology Partner on Patient Enrollment for Tumor-Agnostic Drug Trial Jul 29, 2020 Strata Oncology, BioMed Valley Discoveries Partner on Patient Enrollment for Ulixertinib Study Feb 11, 2020 Natera, Elicio Therapeutics Partner on Phase I/II Pancreatic Cancer Study Jan 22, 2020 B Cell Gene Expression Profiling May Enable Cancer Immunotherapy CDx Test Premium Aug 6, 2019 Sophia Genetics Teams With ADC Therapeutics on Biomarker Discovery for Lymphoma Treatment May 6, 2019 FDA Grants IDE Approval for Almac Diagnostic Services' CDx for Use in Cancer Drug Study Breaking News NIH Earmarks $170M for All of Us Program's Personalized Nutrition Study Taiwanese Firm's IP Asserted in Suit Against Pacific Biosciences Found Partially Unpatentable In Ongoing False Advertising Suit, Judge Allows Natera Counterclaims Against Guardant Health Centogene Strikes Rare Disease Target Discovery Deal With Insilico Medicine Dilated Cardiomyopathy Gene Mutations Point to Possible Therapeutic Strategy Ginkgo Bioworks Acquires Massachusetts COVID-19 Testing Firm The Scan Transplant Tests Edited Pig Kidneys The Associated Press reports a University of Alabama-Birmingham team transplanted genetically modified pig kidneys into a brain-dead human patient. UK Changes Some Gene-Edited Crop Rules A new law may enable gene-edited crops to be sold in the UK within about five years, New Scientist says. Pill Works Against Omicron in Lab Pfizer's antiviral pill to treat SARS-CoV-2 appears to work against the Omicron variant, the Wall Street Journal reports. Nature Papers Find Genetic Risk Factor for Smell, Taste Loss in COVID-19; Analyze TB Granulomas In Nature this week: genome-wide association study find locus linked to the risk COVID-19 patients losing their sense of taste or smell, and more.